Lushang Freda Pharmaceutical Co.,Ltd.

XSSC:600223 Stock Report

Market Cap: CN¥7.0b

Lushang Freda PharmaceuticalLtd Balance Sheet Health

Financial Health criteria checks 6/6

Lushang Freda PharmaceuticalLtd has a total shareholder equity of CN¥4.8B and total debt of CN¥457.4M, which brings its debt-to-equity ratio to 9.6%. Its total assets and total liabilities are CN¥6.1B and CN¥1.3B respectively. Lushang Freda PharmaceuticalLtd's EBIT is CN¥194.1M making its interest coverage ratio -2.2. It has cash and short-term investments of CN¥2.9B.

Key information

9.6%

Debt to equity ratio

CN¥457.35m

Debt

Interest coverage ratio-2.2x
CashCN¥2.94b
EquityCN¥4.76b
Total liabilitiesCN¥1.34b
Total assetsCN¥6.10b

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: 600223's short term assets (CN¥4.3B) exceed its short term liabilities (CN¥1.2B).

Long Term Liabilities: 600223's short term assets (CN¥4.3B) exceed its long term liabilities (CN¥106.7M).


Debt to Equity History and Analysis

Debt Level: 600223 has more cash than its total debt.

Reducing Debt: 600223's debt to equity ratio has reduced from 331.6% to 9.6% over the past 5 years.

Debt Coverage: 600223's debt is well covered by operating cash flow (45.4%).

Interest Coverage: 600223 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies